Unique ID issued by UMIN | UMIN000027495 |
---|---|
Receipt number | R000031509 |
Scientific Title | Evaluation for efficacy of liver function by ingestion of supplement containing plant derived extractive |
Date of disclosure of the study information | 2017/05/26 |
Last modified on | 2018/06/15 18:14:07 |
Evaluation for efficacy of liver function by ingestion of supplement containing plant derived extractive
Evaluation for efficacy of liver function by ingestion of supplement containing plant derived extractive
Evaluation for efficacy of liver function by ingestion of supplement containing plant derived extractive
Evaluation for efficacy of liver function by ingestion of supplement containing plant derived extractive
Japan |
Healthy subjects
Adult |
Others
NO
The aim of this study is to evaluate for the efficacy of the supplement containing plant derived extractive on subjects with high normal liver function.
Safety,Efficacy
Biomarkers of liver function (ALT and AST) before and 4, 8, 12 weeks after the intervention with the test food
Biomarkers of liver function (gamma-GT and ALP), POMS2, LPO, Physical, Hematologic, Blood biochemical, Urinalysis, and Psychological values before and 4, 8, 12 weeks after the intervention with the test food
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
NO
2
Prevention
Food |
Intake of supplement containing plant derived extractive for 12 consecutive weeks (4 capsules, 1 time a day)
Intake of placebo for 12 consecutive weeks (4 capsules, 1 time a day)
20 | years-old | <= |
64 | years-old | >= |
Male and Female
1.Healthy males and females aged 20-64 years old
2.Subjects with BMI greater than 22.0 and less than 30 kg/m^2
3.Subjects who ALT levels were top 40 out of the participants applying to the criteria (both ALT and AST less than 50 U/L)
4.Subjects who has normal or borderline liver function judged by clinical investigator
1.Subjects who constantly use health food richly containing involvement ingredient
2.Subjects who constantly use supplements or drug affecting the liver function
3.Subjects with chronic illness or medication
4.Subjects who has serious illness such as diabetes, liver disease, kidney disease, heart disease
5.Subjects who are in danger of allergy to the study
6.Subjects who have participated in other clinical study within the last one month or have plan to participate other clinical studies
7.Subjects who are judged as unsuitable for the study from clinical measurements for preliminary tests and measurements
8.Subjects who are positive for HCV antibody or HbsAg
9.Subjects who intend to become pregnant or lactating
10.Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire
11.Subjects who are judged as ineligible by clinical investigator
40
1st name | |
Middle name | |
Last name | Yasuhiro Sato |
Shiratori Pharmaceutical Co., Ltd.
Research and Development Dept
2-3-7 Akanehama, Narashino-city, Chiba-pref
047-453-3161
y-sato@shiratori-pharm.co.jp
1st name | |
Middle name | |
Last name | Kotoha Isobe |
TTC Co., Ltd.
Clinical Research Planning Department
Seibu Shinkin Bank Ebisu Bldg.,1-20-2, Ebisunishi, Shibuya-ku, Tokyo
03-5459-5329
k.isobe@ttc-tokyo.co.jp
TTC Co., Ltd.
Shiratori Pharmaceutical Co., Ltd.
Profit organization
NO
2017 | Year | 05 | Month | 26 | Day |
Unpublished
Completed
2017 | Year | 05 | Month | 16 | Day |
2017 | Year | 05 | Month | 27 | Day |
2017 | Year | 05 | Month | 25 | Day |
2018 | Year | 06 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031509